RT Journal Article
SR Electronic
T1 Electrocardiography-Based Prediction of Sudden Cardiac Death in Heart Failure Patients: Application of Artificial Intelligence
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.20.22272659
DO 10.1101/2022.03.20.22272659
A1 Shiraishi, Yasuyuki
A1 Goto, Shinichi
A1 Niimi, Nozomi
A1 Katsumata, Yoshinori
A1 Goda, Ayumi
A1 Takei, Makoto
A1 Saji, Mike
A1 Nishihata, Yosuke
A1 Sano, Motoaki
A1 Fukuda, Keiichi
A1 Kohno, Takashi
A1 Yoshikawa, Tsutomu
A1 Kohsaka, Shun
YR 2022
UL http://medrxiv.org/content/early/2022/03/21/2022.03.20.22272659.abstract
AB Background Although predicting sudden cardiac death (SCD) in patients with heart failure (HF) is critical, the current predictive model is suboptimal. Electrocardiography-based artificial intelligence (ECG-AI) algorithms may better stratify risk. We assessed whether the ECG-AI index established here could better predict SCD in HF and whether the ECG-AI index and conventional predictors of SCD can improve SCD stratification.Methods In a prospective observational study, four tertiary care hospitals in metropolitan Tokyo that enrolled 2,559 patients hospitalized with HF who were successfully discharged after acute decompensation. ECG data collected during the index hospitalization were extracted from the hospitals’ electronic medical record systems. The ECG-AI index is the output from an AI model that was trained to predict the risk of SCD based on ECG input. The association between ECG-AI index and SCD was evaluated with adjustment for left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) class, and competing risk of non-SCD. The outcome measure was a composite of SCD and implantable cardioverter-defibrillator activation. The ECG-AI index was established using a derivation (hospital A) and validation cohort (hospital B), and its ability was evaluated in a test cohort (hospitals C and D).Results The ECG-AI index plus classical predictive guidelines (i.e., LVEF ≤ 35%, NYHA class II–III) significantly improved the discriminative value of SCD (area under the receiver operating characteristic curve, 0.66 vs. 0.59; p=0.017; Delong’s test) with good calibration (p=0.11; Hosmer–Lemeshow test) and improved net reclassification (36%; 95% confidence interval, 9%–64%; p=0.009). The Fine-Gray model considering the competing risk of non-SCD demonstrated that the ECG-AI index was independently associated with SCD (adjusted sub-distributional hazard ratio, 1.25; 95% confidence interval, 1.04–1.49; p=0.015). An increased proportional risk of SCD vs. non-SCD with increasing ECG-AI index was also observed (low, 16.7%; intermediate, 18.5%; high, 28.7% risk; p for trend = 0.023). Similar findings were observed in patients aged ≤75 years with a non-ischemic etiology and an LVEF >35%.Conclusions Among patients with HF, ECG-based AI significantly improved the SCD risk stratification compared to the conventional indication for implantable cardioverter-defibrillators inclusive of LVEF and NYHA class.Competing Interest StatementDr. Shiraishi is affiliated with a department endowed by Nippon Shinyaku Co., Ltd., Medtronic Japan Co., Ltd., and BIOTRONIK JAPAN Inc., and received honoraria from Otsuka Pharmaceuticals Co., Ltd. and Ono Pharmaceuticals Co., Ltd. Dr. Kohsaka received an unrestricted research grant from the Department of Cardiology, Keio University School of Medicine, Bayer Pharmaceuticals Co., Ltd., Daiichi Sankyo Co., Ltd., and Novartis Pharma Co., Ltd. The authors declare no conflicts of interest.Funding StatementThis research was supported by research grants from the Japanese Circulation Society (Y.S. 2019), the SECOM Science and Technology Foundation (Y.S. 2020-2022), and the Uehara Memorial Foundation (Y.S. 2021). This study was also supported by a Grant-in-Aid for Young Scientists (Y.S. JSPS KAKENHI, 18K15860), a Grant-in-Aid for Scientific Research (T.Y. JSPS KAKENHI, 23591062 and 26461088; T.K. 17K09526; S.K. 20H03915), a grant from the Japan Agency for Medical Research and Development (S.K. 201439013C), and Sakakibara Clinical Research Grants for the Promotion of Science (T. Y. 2012-2020).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Keio University School of Medicine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.